Browse News
Filter News
Found 7,135 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Synthetic Biology Industry is Rising Rapidly Up to USD 80.17 Bn by 2033
4/22/2024
The global synthetic biology market size was worth around USD 14.09 billion in 2024 and is predicted to grow around USD 80.17 billion by 2033 with a compound annual growth rate (CAGR) of roughly 18.99% between 2024 and 2033 According to a new report by Nova One Advisor.
-
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
4/20/2024
BioArctic AB announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
-
Red Biotechnology Market Size, CAGR, Trends, Report 2024 to 2033
4/18/2024
According to Vision Research Reports, the global red biotechnology market size was estimated at around USD 492.74 billion in 2023
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
4/18/2024
Kindeva Drug Delivery, a global leader in drug-device combination products, announced that Denis Johnson has joined the company as its new Chief Operating Officer.
-
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
4/15/2024
Applied Therapeutics, Inc. announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
4/12/2024
Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI ® .
-
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
4/10/2024
Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
-
n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024
4/10/2024
n-Lorem, a nonprofit foundation , has announced the dates for its second annual Nano-rare Patient Colloquium, which will be held Oct. 30 & 31 in Cambridge, Mass.
-
Cell and Gene Therapy Market Size to Reach USD 97.33 Bn by 2033
4/5/2024
According to the latest research by nova one advisor, the global cell and gene therapy market size was valued at USD 18.13 billion in 2023 and is anticipated to reach around USD 97.33 billion by 2033, growing at a CAGR of 18.3% from 2024 to 2033.
-
Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors
4/4/2024
Cadenza Bio, Inc., a pioneering preclinical biotechnology company dedicated to developing innovative small-molecule drugs for the treatment of multiple sclerosis and other demyelinating and inflammatory diseases, proudly announces the appointment of Michael A. Panzara, MD, MPH, to its esteemed board of directors.
-
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
-
Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial difficulty. Merz Therapeutics will acquire two commercial medicines from Acorda for $185 million.
-
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
4/3/2024
According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033